NasdaqGS - Nasdaq Real Time Price USD
CG Oncology, Inc. (CGON)
20.41
0.00
(0.00%)
As of 3:52:32 PM EDT. Market Open.
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 5,000 | 5 |
| Sales | 705,000 | 6 |
| Net Shares Purchased (Sold) | -700,000 | 11 |
| Total Insider Shares Held | 4.7M | -- |
| % Net Shares Purchased (Sold) | -13.00% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| POST LEONARD E Director | Sale at price 28.00 per share. | Direct | 28,000 | Mar 17, 2025 |
| POST LEONARD E Director | Conversion of Exercise of derivative security at price 0.60 per share. | Direct | 600 | Mar 17, 2025 |
| POST LEONARD E Director | Sale at price 28.61 per share. | Direct | 28,610 | Feb 18, 2025 |
| POST LEONARD E Director | Conversion of Exercise of derivative security at price 0.60 per share. | Direct | 600 | Feb 18, 2025 |
| POST LEONARD E Director | Sale at price 29.66 per share. | Direct | 29,660 | Jan 13, 2025 |
| POST LEONARD E Director | Conversion of Exercise of derivative security at price 0.60 per share. | Direct | 600 | Jan 13, 2025 |
| POST LEONARD E Director | Sale at price 28.84 per share. | Direct | 28,840 | Dec 16, 2024 |
| POST LEONARD E Director | Conversion of Exercise of derivative security at price 0.60 per share. | Direct | 600 | Dec 16, 2024 |
| SONG HONG FANG Director | Sale at price 28.00 per share. | Indirect | 19,600,000 | Dec 16, 2024 |
| POST LEONARD E Director | Sale at price 34.40 - 34.98 per share. | Direct | 34,542 | Dec 6, 2024 |
| POST LEONARD E Director | Conversion of Exercise of derivative security at price 0.60 per share. | Direct | 600 | Dec 6, 2024 |
| SONG HONG FANG Director | Sale at price 35.36 per share. | Indirect | 23,000,089 | Aug 29, 2024 |
| DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 37.00 per share. | Indirect | 14,800,000 | Jan 29, 2024 |
| DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P. Beneficial Owner of more than 10% of a Class of Security | -- | Direct | -- | Jan 29, 2024 |
| ROCHE CORLEEN M Chief Financial Officer | Purchase at price 37.00 per share. | Direct | 74,000 | Jan 29, 2024 |
| SONG HONG FANG Director | Purchase at price 37.00 per share. | Direct | 9,736,809 | Jan 29, 2024 |
| SONG HONG FANG Director | -- | Indirect | -- | Jan 29, 2024 |
| KASTURI VIJAY M.D. Officer | Purchase at price 37.00 per share. | Direct | 48,655 | Jan 29, 2024 |
| DECHENG VENTURE CAPITAL LTD. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 37.00 per share. | Indirect | 29,600,000 | Jan 29, 2024 |
| DECHENG VENTURE CAPITAL LTD. Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Jan 29, 2024 |
Related Tickers
BCAX Bicara Therapeutics Inc.
13.76
+8.77%
SYRE Spyre Therapeutics, Inc.
13.94
+2.73%
UPB Upstream Bio, Inc.
10.04
+3.40%
MBX MBX Biosciences, Inc.
8.69
+13.68%
CGEM Cullinan Therapeutics, Inc.
8.38
+3.46%
CYTK Cytokinetics, Incorporated
37.68
-0.66%
MLYS Mineralys Therapeutics, Inc.
13.19
-0.38%
IMCR Immunocore Holdings plc
29.45
+0.14%
EWTX Edgewise Therapeutics, Inc.
13.61
+2.33%
XNCR Xencor, Inc.
10.59
-0.09%